Volition

IN PARTNERSHIP WITH:

PROVENTA INTERNATIONAL

STRATEGY DINNER

Discover how cutting-edge epigenetic technologies are shaping the future of biomarker-driven clinical trial design.

DATE

Wed, 18th October 2023

Starts at 6:00PM EST

VENUE

Boston Chops Downtown

52 Temple Place, Boston, MA 02111

Join leading experts in clinical epigenetics and assay development for a collaborative discussion exploring the latest trends in epigenetic drug and biomarker innovation.

Engage in a focused discussion on how nucleosome-based markers are poised to accelerate oncology clinical trials, offering broader applications for monitoring both toxicity and efficacy.

By the end of this discussion, attendees will:

- ✓ Gain a nuanced understanding of the emerging opportunities in biomarker-driven, epigenetic therapeutic development.
- ✓ Acquire insights into the future potential of nucleosome markers as versatile tools for toxicity and response monitoring.

AGENDA

18:00–19:00	**Welcome Cocktails and Networking**
19:00–20:00	**ROUNDTABLE DISCUSSION** ✓ Next-Generation Quantitative Epigenetic Immunoassay Development ✓ In Vivo and Ex Vivo Nucleosome Profiling in Epigenetic Therapeutic Discovery ✓ In Vitro and Clinical Nucleosome Pharmacodynamics Assays **Dr. Terry Kelly**, *Chief Scientific Officer,* **Volition America** *& Chief Innovation Officer* **VolitionRx**
20:00–21:00	**Dinner**
21:00–22:00	**ROUNDTABLE DISCUSSION** ✓ Nucleosomes as Toxicity Markers and Surrogate Endpoints in Oncology Trials ✓ Neutrophil Extracellular Traps: Acute Phase Response Markers ✓ Nucleosomes as Novel Markers for NETs ✓ NETosis as a Driver for Metastasis **Mark Eccleston**, *Chief Technology Officer,* **VolitionRx**
22:00–22:30	**Coffee & Cognacs**

KEY OPINION LEADER

Dr. Terry Kelly - *Chief Scientific Officer* - Volition America & *Chief Innovation Officer* - VolitionRx

Dr. Terry Kelly is the Chief Scientific Officer of Volition America and Chief Innovation Officer of Volition Rx. Originally trained as a Neuroscientist, she went on to study epigenetics as a post-doc where she patented a novel technology (NOME-seq) to map nucleosome positioning and DNA methylation on the same DNA molecule. She received a K99/R00 fellowship but transitioned to industry where she has spent over 10 years focusing on developing novel technologies and seeing them through to commercialization. She currently leads the innovation team at Volition where they focus on chromatic mechanisms underlying health and disease for future product development.

Mark Eccleston - *Chief Technology Officer* - VolitionRx

Dr. Mark Eccleston serves as the Chief Technology Officer and is a scientific founder at Volition. He is a key contributor to Volition's intellectual property, being a named inventor on numerous patents and an author on several scholarly papers. Trained as a polymer chemist, Dr. Eccleston has expanded his expertise to encompass various facets of epigenetics, assay and platform development, as well as implementation. He maintains strong collaborations with both commercial and academic entities and serves as an industrial supervisor for multiple PhD and Master's research programs.

ABOUT VOLITION

Volition is at the forefront of epigenetic immunoassay development, contributing to the drug discovery and development cycle from in-vitro target validation to human clinical trials. Our assays, widely used in oncology and immunotherapy, focus on delivering actionable insights to streamline the entire drug development process. Nu.Q® Discover assays have been validated in preclinical PD studies tracking epigenetic modification levels in response to epigenetic inhibitors with recent data presented at AACR demonstrating a dose-dependent reduction in specific Histone PTM levels by simple liquid biopsy. Our NETosis assay measures the release of Neutrophil Extracellular Traps, aiding in the assessment of acute inflammatory conditions like sepsis and cancer. Our Ex-vivo – Synthetic Sepsis™ platform is designed to screen NETosis modulators and potential activators, providing ex-vivo human data ahead of First-in-Human (FIH) studies. For specialized requirements, we can develop new assays following CLSI development guidelines. Our R&D activities are anchored in Belgium, complemented by an innovation lab in California and offices in Texas, London, and Singapore. For more details and scientific data please visit, volition.com.

CONTACT Kath De Vela kv@proventainternational.com +1 (617) 4534896 ext 325 www.proventainternational.com